Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tyler Shugg

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Heart Rhythm|February 8, 2018
Calcium/calmodulin-dependent protein kinase II regulation of I<sub>Ks</sub> during sustained β-adrenergic receptor stimulationTyler Shugg, Derrick E Johnson, Minghai Shao, et al.
Cardiovascular Drugs and Therapy|November 16, 2019
Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart FailureJasmine A Luzum, Christopher Ting, Edward L Peterson, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|January 13, 2025
Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular DysfunctionTyler Shugg, Tk Nguyen, Xuesi Hua, et al.
Journal of Cardiovascular Electrophysiology|June 24, 2016
Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele CarriersAhmed M Abdelhady, Tyler Shugg, Nancy Thong, et al.
Pediatric Pulmonology|October 28, 2025
Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer RiskTyler Shugg, Katherine A Gallaway, Nick Powell, et al.
Drug Design, Development and Therapy|May 21, 2026
Population Pharmacokinetics and Model-Informed Precision Dosing of Lenalidomide Incorporating Total and Unbound Plasma Concentrations in Renally Impaired Patients with Multiple MyelomaHyeonji Kim, Sung-Soo Park, Suein Choi, et al.
Clinical Pharmacology and Therapeutics|March 7, 2026
Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer DrugsFatimah Alhurayri, Islam R Younis, Shadia I Jalal, et al.
Clinical Pharmacology and Therapeutics|January 10, 2025
Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated CostsHyunwoo Koo, Tayler B Smith, John T Callaghan, et al.
Frontiers in Cardiovascular Medicine|January 2, 2023
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancerElizabeth J Rowe, Tyler Shugg, Reynold C Ly, et al.
JCO Precision Oncology|February 24, 2022
Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid CancersTyler Shugg, Reynold C Ly, Elizabeth J Rowe, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Heart Rhythm|February 8, 2018
Calcium/calmodulin-dependent protein kinase II regulation of I<sub>Ks</sub> during sustained β-adrenergic receptor stimulationTyler Shugg, Derrick E Johnson, Minghai Shao, et al.
Cardiovascular Drugs and Therapy|November 16, 2019
Association of Regulatory Genetic Variants for Protein Kinase Cα with Mortality and Drug Efficacy in Patients with Heart FailureJasmine A Luzum, Christopher Ting, Edward L Peterson, et al.
Journal of Cardiovascular Pharmacology and Therapeutics|January 13, 2025
Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular DysfunctionTyler Shugg, Tk Nguyen, Xuesi Hua, et al.
Journal of Cardiovascular Electrophysiology|June 24, 2016
Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele CarriersAhmed M Abdelhady, Tyler Shugg, Nancy Thong, et al.
Pediatric Pulmonology|October 28, 2025
Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer RiskTyler Shugg, Katherine A Gallaway, Nick Powell, et al.
Drug Design, Development and Therapy|May 21, 2026
Population Pharmacokinetics and Model-Informed Precision Dosing of Lenalidomide Incorporating Total and Unbound Plasma Concentrations in Renally Impaired Patients with Multiple MyelomaHyeonji Kim, Sung-Soo Park, Suein Choi, et al.
Clinical Pharmacology and Therapeutics|March 7, 2026
Pharmacokinetic Drug-Drug Interaction Potential of Oral Anticancer DrugsFatimah Alhurayri, Islam R Younis, Shadia I Jalal, et al.
Clinical Pharmacology and Therapeutics|January 10, 2025
Return of Clinically Actionable Pharmacogenetic Results From Molecular Tumor Board DNA Sequencing Data: Workflow and Estimated CostsHyunwoo Koo, Tayler B Smith, John T Callaghan, et al.
Frontiers in Cardiovascular Medicine|January 2, 2023
Association of QT interval-prolonging drugs with clinical trial eligibility in patients with advanced cancerElizabeth J Rowe, Tyler Shugg, Reynold C Ly, et al.
JCO Precision Oncology|February 24, 2022
Clinical Opportunities for Germline Pharmacogenetics and Management of Drug-Drug Interactions in Patients With Advanced Solid CancersTyler Shugg, Reynold C Ly, Elizabeth J Rowe, et al.
Pageof 4